Darragh, L. B., Oweida, A. J. & Karam, S. D. Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment. Front. Immunol. 9, 3154 (2018).
Lhuillier, C., Rudqvist, N. P., Elemento, O., Formenti, S. C. & Demaria, S. Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med. 11, 40 (2019).
Passelli, K., Reparaz, D., Kinj, R. & Herrera, F. G. Strategies for overcoming tumor resistance to immunotherapy: harnessing the power of radiation therapy. Br. J. Radiol. 9, 1378–1390 (2024).
Hall, E. J. & Giaccia, A. J. Radiobiology for the Radiologist (Harper & Row, 2006).
Tanderup, K., Eifel, P. J., Yashar, C. M., Potter, R. & Grigsby, P. W. Curative radiation therapy for locally advanced cervical cancer: brachytherapy is NOT optional. Int. J. Radiat. Oncol. Biol. Phys. 88, 537–539 (2014).
Grimm, P. D., Blasko, J. C., Sylvester, J. E., Meier, R. M. & Cavanagh, W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 51, 31–40 (2001).
Benedict, S. H. et al. Stereotactic body radiation therapy: the report of AAPM task group 101. Med. Phys. 37, 4078–4101 (2010).
Buchberger, D. S. & Videtic, G. M. M. Stereotactic body radiotherapy for the management of early-stage non-small-cell lung cancer: a clinical overview. JCO Oncol. Pract. 19, 239–249 (2023).
Yu, L. et al. Impact of neoadjuvant chemoradiotherapy on the local recurrence and distant metastasis pattern of locally advanced rectal cancer: a propensity score-matched analysis. Chin. Med. J. 134, 2196–2204 (2021).
Moreira, A. S. L., Cunha, T. M. & Esteves, S. Cervical cancer recurrence — can we predict the type of recurrence? Diagn. Interv. Radiol. 26, 403–410 (2020).
Chen, S. et al. Failure patterns of recurrence and metastasis after intensity-modulated radiotherapy in patients with nasopharyngeal carcinoma: results of a multicentric clinical study. Front. Oncol. 11, 693199 (2021).
Pitakpaiboonkul, P., Jiarpinitnun, C., Pattaranutaporn, P. & Ngamphaiboon, N. Early recurrence, time-to-recurrence, and recurrence patterns: assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M-HNSCC) patients treated with first line platinum-based chemotherapy. Cancer Med. 13, e7047 (2024).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Darragh, L. B. et al. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat. Cancer 3, 1300–1317 (2022). A phase I/Ib trial combining neoadjuvant SBRT with durvalumab (anti-PDL1) in resectable human papillomavirus (HPV)-unrelated locally advanced HNSCC that demonstrated safety and achieved high rates of major pathological responses and complete responses in the 24 Gy expansion cohort.
Herrera, F. G. et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 12, 108–133 (2022). This study demonstrated, in preclinical models and a phase I clinical trial in patients with tumours lacking immune infiltration, that radiation (0.5–1 Gy per fraction) combined with ICB and immunomodulatory agents can increase T cell infiltration into the TME.
Oweida, A. J. et al. STAT3 modulation of regulatory T cells in response to radiation therapy in head and neck cancer. J. Natl Cancer Inst. 111, 1339–1349 (2019).
Lee, N. Y. et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22, 450–462 (2021). The JAVELIN Head and Neck 100 phase III trial showed no benefit from adding avelumab (anti-PDL1) to definitive chemoradiotherapy in locally advanced HNSCC, representing the first negative ICB–chemoradiotherapy combination trial in this setting.
Machiels, J. P. et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 25, 572–587 (2024).
Mell, L. K. et al. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Lancet Oncol. 25, 1576–1588 (2024).
Higgins, K. et al. Concurrent chemoradiation ± atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): results of NRG Oncology/Alliance LU005. Int. J. Radiat. Oncol. Biol. Phys. 120, S2 (2024).
Bradley, J. D. et al. PACIFIC-2: phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC. J. Clin. Oncol. 37, TPS8573 (2019). The Pacific-2 phase III trial failed to demonstrate improved progression-free survival with concurrent durvalumab (anti-PDL1) plus chemoradiotherapy versus chemoradiotherapy alone in unresectable stage III NSCLC, despite the success of sequential durvalumab in the original Pacific trial.
Uppaluri, R. et al. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N. Engl. J. Med. 393, 37–50 (2025). The Keynote-689 phase III trial demonstrated improvement in event-free survival with perioperative pembrolizumab (anti-PD1) plus SOC (surgery followed by adjuvant chemoradiotherapy) versus SOC in resectable locally advanced HNSCC, marking the first successful ICB trial in the curative-intent setting for this disease.
Lorusso, D. et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet 403, 1341–1350 (2024).
Demaria, S. et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J. Immunother. Cancer 9, e002038 (2021).
Galluzzi, L., Aryankalayil, M. J., Coleman, C. N. & Formenti, S. C. Emerging evidence for adapting radiotherapy to immunotherapy. Nat. Rev. Clin. Oncol. 20, 543–557 (2023).
Vozenin, M. C., Montay-Gruel, P., Tsoutsou, P. & Limoli, C. L. Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer. Nat. Rev. Cancer 26, 62–75 (2026).
Yovino, S., Kleinberg, L., Grossman, S. A., Narayanan, M. & Ford, E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest. 31, 140–144 (2013).
Kut, C. et al. Developing the POTOMAC model: a novel prediction model to study the impact of lymphopenia kinetics on survival outcomes in head and neck cancer via an ensemble tree-based machine learning approach. JCO Clin. Cancer Inf. 7, e2300058 (2023).
Prades-Sagarra, E., Yaromina, A. & Dubois, L. J. Understanding the impact of radiation-induced lymphopenia: preclinical and clinical research perspectives. Clin. Transl. Radiat. Oncol. 49, 100852 (2024).
Zhang, Y., Huang, C. & Li, S. Influence of treatment-related lymphopenia on the efficacy of immune checkpoint inhibitors in lung cancer: a meta-analysis. Front. Oncol. 13, 1287555 (2023).
Pike, L. R. G. et al. The impact of radiation therapy on lymphocyte count and survival in metastatic cancer patients receiving PD-1 immune checkpoint inhibitors. Int. J. Radiat. Oncol. Biol. Phys. 103, 142–151 (2019).
Ellsworth, S. G. et al. Lymphocyte depletion rate as a biomarker of radiation dose to circulating lymphocytes during fractionated partial-body radiation therapy. Adv. Radiat. Oncol. 7, 100959 (2022).
Wu, G. et al. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer. BMC Cancer 19, 977 (2019).
Darragh, L. B. et al. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat. Commun. 13, 7015 (2022). This study demonstrated that elective nodal irradiation impairs the systemic immune response generated by a combination of radiation and immunotherapy in HNSCC by reducing antigen-specific CD4+ T cells locally and systemically, leading to increased local and distant tumour growth compared with tumour-only radiation approaches.
Knitz, M. W. et al. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis. J. Immunother. Cancer 9, e001955 (2021).
Leidner, R. et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J. Immunother. Cancer 9, e002485 (2021). A phase Ib trial combining SBRT and nivolumab (anti-PD1) in locally advanced HNSCC demonstrating high rates of major pathological response and tumour downstaging after pathological evaluation.
Formenti, S. C. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 24, 1845–1851 (2018).
Altorki, N. K. et al. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 22, 824–835 (2021).
Chiang, C. L. et al. Survival outcome analysis of stereotactic body radiotherapy and immunotherapy (SBRT-IO) versus SBRT-alone in unresectable hepatocellular carcinoma. Liver Cancer 13, 265–276 (2024).
Klug, F. et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589–602 (2013).
Gunther, J. R. et al. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial. Lancet Haematol. 11, e521–e529 (2024). A pilot trial treating patients with mucosa-associated lymphoid tissue (MALT) lymphoma with 4 Gy (2 Gy per fraction) demonstrated high rates of local tumour control and minimal toxicity.
Zebley, C. C. & Youngblood, B. Mechanisms of T cell exhaustion guiding next-generation immunotherapy. Trends Cancer 8, 726–734 (2022).
Passaro, A. et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell 187, 1617–1635 (2024).
Lussier, D. M. et al. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc. Natl Acad. Sci. USA 118, e2102611118 (2021). This study demonstrated that irradiation of a mouse sarcoma cell line with 4–9 Gy could induce neoantigens, rendering previously non-immunogenic tumours susceptible to ICB.
du Bois, H., Heim, T. A. & Lund, A. W. Tumor-draining lymph nodes: at the crossroads of metastasis and immunity. Sci. Immunol. 6, eabg3551 (2021).
Chen, J. et al. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer Cell 43, 361–379.e10 (2025). Intestinal low-dose radiation synergizes with ICB in both preclinical studies and patients with metastatic cancer to increase dendritic cell trafficking to TDLNs.
Guo, S. et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct. Target. Ther. 8, 205 (2023).
Piper, M. et al. Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis. Cancer Cell 41, 950–969.e6 (2023).
Hou, Y. et al. Radiotherapy enhances metastasis through immune suppression by inducing PD-L1 and MDSC in distal sites. Clin. Cancer Res. 30, 1945–1958 (2024). Single-fraction 20 Gy radiotherapy increases metastasis through induction of PDL1 expression and MDSC recruitment, which can be reversed by blocking PDL1 or MDSCs.
Wang, J. et al. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Sci. Adv. 10, eadk1827 (2024).
Shen, Y. et al. Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+ PD-1+ TCF-1+ T cells in the tumor-draining lymph node. Nat. Commun. 16, 3522 (2025).
Telarovic, I. et al. Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease. Nat. Commun. 15, 5500 (2024). Irradiation of TDLNs was shown to decrease local and distant tumour control when done concurrently with ICB, but not when lymph node irradiation is delayed or given adjunctly.
Barker, H. E., Paget, J. T., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409–425 (2015).
Zhao, D. et al. Dual effects of radiotherapy on tumor microenvironment and its contribution towards the development of resistance to immunotherapy in gastrointestinal and thoracic cancers. Front. Cell Dev. Biol. 11, 1266537 (2023).
Qiu, J. et al. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat. Cancer 4, 43–61 (2023).
Qiu, J. et al. Targeting interferon-driven inflammatory memory prevents epigenetic evolution of cancer immunotherapy resistance. Preprint at bioRxiv https://doi.org/10.1101/2024.08.13.607862 (2024).
Reticker-Flynn, N. E. et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell 185, 1924–1942.e23 (2022). This study provided a mechanistic basis for the well-established clinical correlation between lymph node involvement and poor clinical prognosis across solid malignancies by showing that lymph node colonization by tumour cells induces broad immune tolerance.
Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016). This study revealed that prolonged IFN signalling in tumours drives adaptive resistance to ICB through STAT1-mediated upregulation of multiple inhibitory pathways and demonstrates that disrupting tumour IFN signalling can restore sensitivity to ICB monotherapy in otherwise resistant tumours.
Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).
Jacquelot, N. et al. Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 29, 846–861 (2019).
Schaue, D. et al. Radiation and inflammation. Semin. Radiat. Oncol. 25, 4–10 (2015).
Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843–852 (2014).
Liang, H. et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat. Commun. 8, 1736 (2017).
Wang, J., Xu, Z., Wang, Z., Du, G. & Lun, L. TGF-beta signaling in cancer radiotherapy. Cytokine 148, 155709 (2021).
Jobling, M. F. et al. Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat. Res. 166, 839–848 (2006).
Farhood, B. et al. TGF-beta in radiotherapy: mechanisms of tumor resistance and normal tissues injury. Pharmacol. Res. 155, 104745 (2020).
Derynck, R., Turley, S. J. & Akhurst, R. J. TGFβ biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9–34 (2021).
Abdelhakiem, M. K. et al. TH2 cells are associated with tumor recurrence following radiation. Cancers 16, 1586 (2024).
Han, G., Zhang, H., Xie, C. H. & Zhou, Y. F. TH2-like immune response in radiation-induced lung fibrosis. Oncol. Rep. 26, 383–388 (2011).
Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487–502.e15 (2017). This study demonstrated that effective cancer immunotherapy requires coordinated immune responses across multiple anatomical sites rather than being limited to the TME.
Saddawi-Konefka, R. et al. Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. Nat. Commun. 13, 4298 (2022). Surgical removal or irradiation of the TDLNs was shown here to decrease local tumour control in mouse models of HNSCC treated with ICB.
Saddawi-Konefka, R., Schokrpur, S. & Gutkind, J. S. Let it be: preserving tumor-draining lymph nodes in the era of immuno-oncology. Cancer Cell 42, 930–933 (2024).
van Pul, K. M., Fransen, M. F., van de Ven, R. & de Gruijl, T. D. Immunotherapy goes local: the central role of lymph nodes in driving tumor infiltration and efficacy. Front. Immunol. 12, 643291 (2021).
Saddawi-Konefka, R. et al. The tumor-sentinel lymph node immuno-migratome reveals CCR7(+) dendritic cells drive response to sequenced immunoradiotherapy. Nat. Commun. 16, 6578 (2025). This study demonstrates that tumour-directed radiation before ICB promotes immune cell migration to the TDLNs, and this can be effectively disrupted by lymph node radiation or surgical excision.
Matsuda, T. et al. TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. Oncoimmunology 8, e1588085 (2019).
Miron, M. et al. Human lymph nodes maintain TCF-1(hi) memory T cells with high functional potential and clonal diversity throughout life. J. Immunol. 201, 2132–2140 (2018).
Schenkel, J. M. et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+) CD8(+) T cells in tumor-draining lymph nodes. Immunity 54, 2338–2353.e6 (2021).
Molodtsov, A. K. et al. Resident memory CD8(+) T cells in regional lymph nodes mediate immunity to metastatic melanoma. Immunity 54, 2117–2132.e7 (2021).
Connolly, K. A. et al. A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci. Immunol. 6, eabg7836 (2021).
Escobar, G. et al. Tumor immunogenicity dictates reliance on TCF1 in CD8(+) T cells for response to immunotherapy. Cancer Cell 41, 1662–1679.e7 (2023).
Marciscano, A. E. et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin. Cancer Res. 24, 5058–5071 (2018). Elective nodal irradiation was shown to decrease local tumour control in a mouse model of melanoma by decreasing antigen-specific CD8+ T cells in the TME.
Buchwald, Z. S. et al. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J. Immunother. Cancer 8, e000867 (2020). This study demonstrated that TDLNs are a critical reserve for stem-like CD8+ T cells and because these cells are essential for the radiation-induced abscopal effect, targeting these lymph nodes with radiation prevents systemic antitumour immunity.
Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379, 2342–2350 (2018). This pivotal phase III trial established durvalumab (anti-PD1) maintenance therapy as the new standard of care for stage III unresectable NSCLC.
Zhou, H. et al. Cancer immunotherapy responses persist after lymph node resection. Preprint at bioRxiv https://doi.org/10.1101/2023.09.19.558262 (2024).
Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731–2738 (2004).
Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701–708 (2020).
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581–594.e12 (2018).
Reiter, J. G. et al. Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases. Nat. Genet. 52, 692–700 (2020).
Pereira, E. R. et al. Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science 359, 1403–1407 (2018).
Leong, S. P., Naxerova, K., Keller, L., Pantel, K. & Witte, M. Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. Clin. Exp. Metastasis 39, 159–179 (2022).
Lukens, J. N., Huang, A. C., Minn, A. J. III & Maity, A. Immune profiling of ‘Radvax’ abscopal responses in metastatic melanoma patients progressing on anti-PD1 therapy treated with hypofractionated radiotherapy (HFRT) to one lesion combined with pembrolizumab. Int. J. Radiat. Oncol. Biol. Phys. 120, S89–S90 (2024).
Lukens, J. N. et al. Final results of a phase I ‘RadVax’ trial of hypofractionated radiation combined with pembrolizumab in patients with metastatic solid tumors. J. Clin. Oncol. 39, 2576 (2021).
Naxerova, K. et al. Origins of lymphatic and distant metastases in human colorectal cancer. Science 357, 55–60 (2017).
Zhang, C. et al. Mapping the spreading routes of lymphatic metastases in human colorectal cancer. Nat. Commun. 11, 1993 (2020).
Ullah, I. et al. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. J. Clin. Invest. 128, 1355–1370 (2018).
Venet, D. et al. Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome. eBioMedicine 56, 102793 (2020).
Sher, D. J. et al. Efficacy and quality-of-life following involved nodal radiotherapy for head and neck squamous cell carcinoma: the INRT-AIR phase II clinical trial. Clin. Cancer Res. 29, 3284–3291 (2023). A phase II clinical trial in patients with HNSCC that showed omitting ENI could improve patient’s quality-of-life without increasing elective nodal recurrence.
Holzgreve, A. et al. PSMA-PET/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw. Open 8, e2452971 (2025).
Sher, D. J. et al. Prospective phase 2 study of radiation therapy dose and volume de-escalation for elective neck treatment of oropharyngeal and laryngeal cancer. Int. J. Radiat. Oncol. Biol. Phys. 109, 932–940 (2021).
Seiwert, T. Y. et al. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann. Oncol. 30, 297–302 (2019).
Castelli, J. et al. 852MO REWRITE-GORTEC 2018-02: radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck. Ann. Oncol. 35, S615 (2024). This phase II clinical trial in patients with HNSCC demonstrated that reduced prophylactic neck irradiation combined with durvalumab (anti-PDL1) achieved excellent local control rates, suggesting that selective volume reduction may be feasible with concurrent immunotherapy without compromising outcomes.
Ma, T. M. et al. High recurrence for HPV-positive oropharyngeal cancer with neoadjuvant radiation therapy to gross disease plus immunotherapy: analysis from a prospective phase Ib/II clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 117, 348–354 (2023). This phase Ib/II clinical trial in HPV-related HNSCC had high rates of locoregional nodal recurrence in patients treated with combination neoadjuvant radiation and both durvalumab (anti-PDL1) and tremelimumab (anti-CTLA-4), without ENI.
Sher, D. J. et al. Acute toxicity and efficiency outcomes in the DARTBOARD randomized trial of daily adaptive radiotherapy for head and neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 117, e6 (2023).
Schoenfeld, J. D. Proceed with caution: eliminating elective nodal irradiation with immunotherapy for head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 117, 355–356 (2023).
Soeung, M. et al. Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence. Nat. Commun. 16, 10474 (2025).
Gadwa, J. et al. Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC. Cell Rep. Med. 4, 101150 (2023).
Huang, D., Lynch, C., Pitroda, S. P. & Weichselbaum, R. R. Facts and hopes in radioimmunotherapy of oligometastatic disease. Clin. Cancer Res. 31, 2556–2564 (2025).
Palma, D. A. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J. Clin. Oncol. 38, 2830–2838 (2020). This phase II clinical trial demonstrated improved overall survival in multiple oligometastatic cancers when patients were treated with SABR to multiple lesions.
Allen, B. M. et al. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat. Med. 26, 1125–1134 (2020).
Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152–164 (2021).
Qin, S. S. et al. Intertumoral genetic heterogeneity generates distinct tumor microenvironments in a novel murine synchronous melanoma model. Cancers 13, 2293 (2021).
McBride, S. et al. Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma. J. Clin. Oncol. 39, 30–37 (2021). A phase II clinical trial combining nivolumab and SBRT to a single metastatic lesion that failed to show an abscopal effect in metastatic HNSCC.
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05721755 (2023).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT03546582 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT06211335 (2023).
Cantor, D. J. et al. Brief report: long-term follow-up of adjuvant pembrolizumab after locally ablative therapy for oligometastatic NSCLC. JTO Clin. Res. Rep. 5, 100667 (2024).
Bauml, J. M. et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncol. 5, 1283–1290 (2019).
Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A. & Formenti, S. C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1, 365–372 (2013).
Welsh, J. W. et al. Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses. Cancer Immunol. Res. 7, 1903–1909 (2019).
Menon, H. et al. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J. Immunother. Cancer 7, 237 (2019).
Wei, J. et al. Sequence of alphaPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci. Immunol. 6, eabg0117 (2021).
Young, K. H. et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS ONE 11, e0157164 (2016).
Gunderson, A. J. & Young, K. H. Exploring optimal sequencing of radiation and immunotherapy combinations. Adv. Radiat. Oncol. 3, 494–505 (2018).
Zandberg, D. P. et al. 856MO — a randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis. Ann. Oncol. 34, S557–S558 (2023).
Pearson, A. T. et al. A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: the PATHWay study. J. Clin. Oncol. 42, 6008 (2024).
Haddad, R. et al. Atezolizumab in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomized clinical trial. JAMA 333, 1599–1607 (2025).
Mowery, Y. M. et al. Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. Lancet 404, 2053–2064 (2024).
Mempel, T. R., Henrickson, S. E. & Von Andrian, U. H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427, 154–159 (2004).
Azarov, I., Peskov, K., Helmlinger, G. & Kosinsky, Y. Role of T cell-to-dendritic cell chemoattraction in T cell priming initiation in the lymph node: an agent-based modeling study. Front. Immunol. 10, 1289 (2019).
Linderman, J. J. et al. Characterizing the dynamics of CD4+ T cell priming within a lymph node. J. Immunol. 184, 2873–2885 (2010).
Moore, C. et al. Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) in preclinical models enhances single-agent immune checkpoint blockade. Int. J. Radiat. Oncol. Biol. Phys. 110, 1306–1316 (2021). This preclinical study demonstrates that PULSAR increases ICB efficacy, suggesting that extended interfraction intervals may better synergize with ICB to preserve the immune cell function between doses.
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04779489 (2024).
Suzuki, K. et al. Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases. Sci. Immunol. 8, eadd4947 (2023).
Goswami, S., Pauken, K. E., Wang, L. & Sharma, P. Next-generation combination approaches for immune checkpoint therapy. Nat. Immunol. 25, 2186–2199 (2024).
Lin, X. et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol. Cancer 23, 108 (2024).
Kamada, T. et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc. Natl Acad. Sci. USA 116, 9999–10008 (2019).
Kumagai, S. et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 21, 1346–1358 (2020).
Geels, S. N. et al. Interruption of the intratumor CD8(+) T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell 42, 1051–1066.e7 (2024).
Kim, M. J. et al. Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells. Nat. Immunol. 24, 148–161 (2023).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05053737 (2021).
Huang, X. et al. Immunogenic chemotherapy: great potential for improving response rates. Front. Oncol. 13, 1308681 (2023).
Park, Y. H. et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat. Commun. 11, 6175 (2020).
Emmons, T. R. et al. Abstract 3791: tumor cells surviving DNA damage acquire antigen presenting functions to stimulate anti-tumor immunity. Cancer Res. 85, 3791–3791 (2025).
Jagodinsky, J. C. et al. Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade. Sci. Transl. Med. 16, eadk0642 (2024). This study demonstrated that a single fraction of heterogeneous intratumoural radiotherapy induces dose-dependent immunomodulatory effects, with high, medium and lose doses each activating distinct immune mechanisms that together support a better response to ICB than homogeneous irradiation.
Ghaderi, N. et al. A century of fractionated radiotherapy: how mathematical oncology can break the rules. Int. J. Mol. Sci. 23, 1316 (2022).
Ghaderi, N., Jung, J. H., Odde, D. J. & Peacock, J. Clinically validated model predicts the effect of intratumoral heterogeneity on overall survival for non-small cell lung cancer (NSCLC) patients. Comput. Methods Prog. Biomed. 212, 106455 (2021).
Gadwa, J. et al. Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment. J. Immunother. Cancer 13, e010405 (2025).
Zappasodi, R., Merghoub, T. & Wolchok, J. D. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell 33, 581–598 (2018).
Ho, E. et al. Personalized treatment in HPV + oropharynx cancer using genomic adjusted radiation dose. J. Clin. Invest. 135, e194073 (2025).
John, J. et al. Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors. Front. Immunol. 13, 992630 (2022).
Xiao, T. et al. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications. Nat. Rev. Cancer 24, 338–355 (2024).
Forsyth, K. S., Jiwrajka, N., Lovell, C. D., Toothacre, N. E. & Anguera, M. C. The conneXion between sex and immune responses. Nat. Rev. Immunol. 24, 487–502 (2024).
Fu, X. et al. The inter-link of ageing, cancer and immunity: findings from real-world retrospective study. Immun. Ageing 20, 75 (2023).
Zhivaki, D. et al. Correction of age-associated defects in dendritic cells enables CD4(+) T cells to eradicate tumors. Cell 187, 3888–3903.e18 (2024).
Zhuang, X. et al. Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis. Nature 637, 184–194 (2025).
Houlahan, K. E. et al. Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity. Science 384, eadh8697 (2024).
Golonko, A. et al. Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review. Cell Death Dis. 15, 254 (2024).
Gould, A. L. et al. Microbiome interactions shape host fitness. Proc. Natl Acad. Sci. USA 115, E11951–E11960 (2018).
Gustafson, M. P. et al. Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. J. Immunother. Cancer 9, e001872 (2021).
Haynes, L. Aging of the immune system: research challenges to enhance the health span of older adults. Front. Aging 1, 602108 (2020).
Lei, P.-J. et al. Aging-induced changes in lymphatic muscle cell transcriptomes are associated with reduced pumping of peripheral collecting lymphatic vessels in mice. Dev. Cell 60, 1118–1133.e5 (2025).
Irelli, A., Sirufo, M. M., D’Ugo, C., Ginaldi, L. & De Martinis, M. Sex and gender influences on cancer immunotherapy response. Biomedicines 8, 232 (2020).
Zheng, D. et al. Sexual dimorphism in the incidence of human cancers. BMC Cancer 19, 684 (2019).
Zhou, Y. et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct. Target. Ther. 9, 132 (2024).
Holder, A. M. et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat. Rev. Cancer 24, 498–512 (2024).
Wang, N. H. et al. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. Ann. Transl. Med. 10, 1406 (2022).
Tay, R. E., Richardson, E. K. & Toh, H. C. Revisiting the role of CD4(+) T cells in cancer immunotherapy — new insights into old paradigms. Cancer Gene Ther. 28, 5–17 (2021).
Kagamu, H. et al. CD4(+) T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy. Cancer Immunol. Res. 8, 334–344 (2020).
Laheurte, C. et al. Distinct prognostic value of circulating anti-telomerase CD4(+) Th1 immunity and exhausted PD-1(+)/TIM-3(+) T cells in lung cancer. Br. J. Cancer 121, 405–416 (2019).
Duhen, R. et al. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat. Commun. 12, 1047 (2021).
Holm, J. S. et al. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nat. Commun. 13, 1935 (2022).
Brueckl, W. M. Dynamic change of CD8(+) T cell: immunotherapy fate tell? Transl. Lung Cancer Res. 12, 944–947 (2023).
Kang, D. H. et al. Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors. Cancer Immunol. Immunother. 71, 579–588 (2022).
Liu, Y. et al. Predicting patient outcomes after treatment with immune checkpoint blockade: a review of biomarkers derived from diverse data modalities. Cell Genom. 4, 100444 (2024).
Sultan, H. et al. Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature 632, 182–191 (2024).
Li, S. et al. A high interferon gamma signature of CD8(+) T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer. Front. Immunol. 13, 1056144 (2022).
Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017).
Xu, T., Lu, J. & An, H. The relative change in regulatory T cells/T helper lymphocytes ratio as parameter for prediction of therapy efficacy in metastatic colorectal cancer patients. Oncotarget 8, 109079–109093 (2017).
Sinicrope, F. A. et al. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 137, 1270–1279 (2009).
Liu, Q., Sun, Z. & Chen, L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell 11, 549–564 (2020).
Han, J., Khatwani, N., Searles, T. G., Turk, M. J. & Angeles, C. V. Memory CD8(+) T cell responses to cancer. Semin. Immunol. 49, 101435 (2020).
Piper, M. et al. Targeting Treg-expressed STAT3 enhances NK-mediated surveillance of metastasis and improves therapeutic response in pancreatic adenocarcinoma. Clin. Cancer Res. 28, 1013–1026 (2022).
Ettinger, D. S. et al. Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 20, 497–530 (2022).
Anagnostou, V. et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat. Med. 29, 2559–2569 (2023).
Kelly, R. J. et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat. Med. 30, 1023–1034 (2024).
Bittla, P. et al. Exploring circulating tumor DNA (ctDNA) and its role in early detection of cancer: a systematic review. Cureus 15, e45784 (2023).
Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976–1986 (2018).
Luoma, A. M. et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell 185, 2918–2935.e29 (2022).
Bassez, A. et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat. Med. 27, 820–832 (2021).
Jia, Q. et al. Tracking neoantigens by personalized circulating tumor DNA sequencing during checkpoint blockade immunotherapy in non-small cell lung cancer. Adv. Sci. 7, 1903410 (2020).
Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8, 9 (2023).
Valpione, S. et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat. Commun. 12, 4098 (2021).